Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,610.00
Bid: 1,609.50
Ask: 1,610.50
Change: -2.00 (-0.12%)
Spread: 1.00 (0.062%)
Open: 1,607.50
High: 1,614.00
Low: 1,594.00
Prev. Close: 1,612.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Covid-19 Hit Sends National Express Lower

Thu, 13th Aug 2020 11:02

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 100 - WINNERS

----------

Just Eat Takeaway, up 2.6%. The online food delivery platform was counting gains after it posted positive interim results on Wednesday. The stock closed up 3.7% on Wednesday.

----------

FTSE 100 - LOSERS

----------

Phoenix Group, down 3.7%, Legal & General, down 1.8%, Aviva, down 2.3%. GlaxoSmithKline, down 2.3%. Royal Dutch Shell A, down 2.2%, Shell B, down 2.1%. The stocks listed in this section all went ex-dividend on Thursday, meaning new buyers no longer qualify for the latest payout.

----------

FTSE 250 - WINNERS

----------

Watches of Switzerland, up 16%. The luxury timepiece retailer said it delivered a strong performance in its maiden year as a public company. For the financial year ended April 26, revenue was up 6% to GBP819.3 million from GBP797.7 million in financial 2019, and adjusted pretax profit was GBP49.4 million, up 86% from GBP26.5 million. For financial 2021, Watches of Switzerland expects revenue in a range between GBP840 million to GBP860 million, on the basis of a continued strong luxury watch market in the UK and US. The company re-opened the majority of its stores during the first quarter, with July registering 7.4% growth in sales versus a year ago, the first full month when the majority of the network was re-opened. June sales were up 0.3%, while May registered a 83% drop.

----------

FTSE 250 - LOSERS

----------

National Express, down 12%. The transport company swung to a bruising loss during a first-half that was focused on limiting the damage from Covid-19, which has battered the public transport sector. The bus, coach and train operator swung to a GBP122.2 million pretax loss in the six months to June 30 from a GBP88.4 million profit a year earlier. Revenue dropped 23% to GBP1.03 billion from GBP1.34 billion. There was no interim dividend, as previously guided, following a 5.16p payout a year ago. There is also no annual profit guidance, due to Covid-19 uncertainty.

----------

Renishaw, down 11%. The British engineering company warned of the continuation of "very challenging" macroeconomic conditions due to the Covid-19 pandemic. For the financial year that ended June 30 pretax profit fell to GBP3.2 million down 97% from GBP109.9 million recorded a year ago. The sharp drop was attributed to restructuring costs, losses in value of financial instruments and financial expenses. Annual revenue fell 11% to GBP510.2 million from GBP574.0 million. Metrology division revenue was lower by 11% at GBP475.2 million, largely as a result of trade tensions between the US and China, weaker demand in the machine tool sector, and the impact of the pandemic. Healthcare revenue decreased by 15% to GBP35.0 million, with Covid-19 causing delays in orders, shipments, installations and postponements of elective surgery. It stated that a final dividend will not be declared in 2020.

----------

TUI, down 4.2%. The Anglo-German holiday firm offered a bleak picture to investors after third-quarter results highlighted how severely hit the travel sector was due to Covid-19 lockdown. Tui reported a pretax loss of EUR1.46 billion for the period ended June 30, swinging from a EUR60 million profit a year before, as revenue plunged 98% to EUR75 million. Third-quarter underlying loss before interest and tax amounted to EUR1.1 billion due to suspension of operations for the majority part of the quarter, resulting in impairment charges and costs arising from ineffective hedging contracts. For the nine months to June-end, the company's revenue fell 41% To EUR6.71 billion, resulting in a sharply widened pretax loss of EUR2.34 billion from a EUR323.3 million loss a year ago. The nine-month underlying Ebit loss amounted to EUR2.0 billion, an increase of EUR1.8 billion versus a year prior, reflected underlying costs of EUR1.3 billion from business suspension since March, impairments triggered totalling EUR410 million, and net costs from ineffective hedges amounting to EUR189 million.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

ASOS, up 3.5%. The online fashion retailer was upgraded to Hold from Sell by Liberum. ASOS on Wednesday said its annual sales and profit are likely to be "significantly ahead of market expectations" as customer returns did not increase as fast as expected.

----------

By Neetika Kurup; neetikakurup@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.